We are live on
!
Find out more
Westfield Capital Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
49.45%
This Fund
S&P 500
This Quarter
Est. Return
+19.96%
1 Year Est. Return
+49.45%
3 Year Est. Return
+148.08%
5 Year Est. Return
+180.9%
10 Year Est. Return
+972.69%
AUM
$13.1B
AUM Growth
+$1.42B
(+12%)
Cap. Flow
-$642M
Cap. Flow
% of AUM
-4.89%
Top 10 Holdings %
Top 10 Hldgs %
18.52%
Holding
284
New
44
Increased
49
Reduced
142
Closed
38
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$163M |
| 2 |
Caterpillar
CAT
|
+$85.4M |
| 3 |
Analog Devices
ADI
|
+$53.7M |
| 4 |
Advance Auto Parts
AAP
|
+$39.7M |
| 5 |
FISV
Fiserv Inc
FISV
|
+$37.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$142M |
| 2 |
Costco
COST
|
+$77.5M |
| 3 |
Vail Resorts
MTN
|
+$76.9M |
| 4 |
CELG
Celgene Corp
CELG
|
+$73.2M |
| 5 |
Mettler-Toledo International
MTD
|
+$67.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.26% |
| 2 | Healthcare | 16.35% |
| 3 | Consumer Discretionary | 13.11% |
| 4 | Industrials | 12.97% |
| 5 | Financials | 10.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Nektar Therapeutics
NKTR
$2.58B
| $848K | 0.01% |
1,683
| – | – |
|
|
UNVR
227
DELISTED
Univar Solutions Inc.
UNVR
| $613K | ﹤0.01% |
27,650
-1,123,287
| -98% | -$24.2M |
|
228
Intel
INTC
$513B
| $527K | ﹤0.01% |
+9,812
| New | +$498K |
|
|
EXAS
229
DELISTED
Exact Sciences
EXAS
| $520K | ﹤0.01% |
6,000
| – | – |
|
230
Boyd Gaming
BYD
$6.06B
| $515K | ﹤0.01% |
18,820
| – | – |
|
|
UCTT
231
Ultra Clean Holdings
UCTT
$3.95B
| $491K | ﹤0.01% |
47,450
-1,110,543
| -96% | -$11.9M |
|
232
West Pharmaceutical
WST
$24.9B
| $408K | ﹤0.01% |
3,700
| – | – |
|
|
TRVG
233
trivago
TRVG
$397M
| $393K | ﹤0.01% |
18,180
+4,000
| +28% | +$110K |
|
234
Veeva Systems
VEEV
$37.4B
| $368K | ﹤0.01% |
+2,900
| New | +$327K |
|
235
Vistra
VST
$47.4B
| $357K | ﹤0.01% |
+13,700
| New | +$346K |
|
236
Citigroup
C
$226B
| $324K | ﹤0.01% |
+5,200
| New | +$323K |
|
237
Groupon
GRPN
$1.02B
| $311K | ﹤0.01% |
+4,385
| New | +$309K |
|
238
Ventas
VTR
$47.9B
| $301K | ﹤0.01% |
4,719
| – | – |
|
239
United Airlines
UAL
$42.1B
| $295K | ﹤0.01% |
+3,700
| New | +$312K |
|
240
Nokia
NOK
$52.3B
| $292K | ﹤0.01% |
+51,100
| New | +$313K |
|
241
Ciena
CIEN
$58.4B
| $284K | ﹤0.01% |
+7,600
| New | +$295K |
|
|
GTLS
242
DELISTED
Chart Industries
GTLS
| $272K | ﹤0.01% |
+3,000
| New | +$242K |
|
243
Tandem Diabetes Care
TNDM
$1.56B
| $267K | ﹤0.01% |
+4,200
| New | +$221K |
|
|
AXNX
244
DELISTED
Axonics, Inc. Common Stock
AXNX
| $261K | ﹤0.01% |
+10,900
| New | +$198K |
|
|
QTNT
245
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $217K | ﹤0.01% |
+603
| New | +$212K |
|
246
SLB Ltd
SLB
$75B
| $210K | ﹤0.01% |
+4,824
| New | +$209K |
|
247
Archer Daniels Midland
ADM
$36.9B
| – | – |
-113,415
| Closed | -$4.65M |
|
248
Advanced Energy
AEIS
$13B
| – | – |
-173,030
| Closed | -$7.43M |
|
249
A.O. Smith
AOS
$8.7B
| – | – |
-87,760
| Closed | -$3.75M |
|
250
Aptiv
APTV
$10.3B
| – | – |
-5,852
| Closed | -$360K |
|
Similar funds
OAG
JG
CHP
SC
Westfield Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Westfield Capital Management held 284 positions worth $13.1B, up 12% from $11.7B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Westfield Capital Management withdrew a net $642M in Q1 2019, closing 38 positions and reducing 142 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $142M position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Westfield Capital Management opened a new position in Bristol-Myers Squibb worth $156M.
- Westfield Capital Management's largest Q1 2019 buy was Bristol-Myers Squibb: 3,278,241 shares worth $156M.
- Westfield Capital Management added most to T-Mobile US in Q1 2019, an estimated $32.3M increase.
- Westfield Capital Management's biggest Q1 2019 reduction was Vail Resorts, cutting an estimated $76.9M.
- Westfield Capital Management fully exited Jazz Pharmaceuticals in Q1 2019, selling an estimated $142M.
- Westfield Capital Management's ten largest holdings make up 19% of its $13.1B portfolio in Q1 2019.
- Westfield Capital Management opened 44 new positions and closed 38 in Q1 2019.
- Westfield Capital Management's portfolio value rose 12% quarter-over-quarter to $13.1B.
Based on Westfield Capital Management's 13F filing for Q1 2019, filed 14 May 2019.